MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MYCN amplification	Small Cell Lung Cancer	MYCN amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CDKN2A mutation + TP53 mutation	Small Cell Lung Cancer	CDKN2A mutation + TP53 mutation	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
TP53 mutation	Ovarian Cancer	TP53 mutation	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
TP53 mutation	Squamous Cell Carcinoma of Head and Neck	TP53 mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MYCL amplification	Small Cell Lung Cancer	MYCL amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
TP53 mutation	Triple Negative Breast Cancer	TP53 mutation	Triple Negative Breast Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 overexpression	Ovarian Cancer	CCNE1 overexpression	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
CCNE1 amplification	Solid Tumor	CCNE1 amplification	Solid Tumor	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MSI-H/dMMR	Endometrial Adenocarcinoma	MSI-H/dMMR	Endometrial Adenocarcinoma	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
BRCA2 mutation	Head and Neck Cancer	BRCA2 mutation	Head and Neck Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
BRCA1 mutation	Head and Neck Cancer	BRCA1 mutation	Head and Neck Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
ATRX mutation	Neuroblastoma	ATRX mutation	Neuroblastoma	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
CCNE1 overexpression	Endometrial Cancer	CCNE1 overexpression	Endometrial Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
BRCA2 mutation	Ovarian Cancer	BRCA2 mutation	Ovarian Cancer	olaparib + AZD1775 Sensitive: C3 – Early Trials olaparib + AZD1775 Sensitive : C3	olaparib + AZD1775 Sensitive: C3 – Early Trials olaparib + AZD1775 Sensitive : C3
BRCA1 mutation	Ovarian Cancer	BRCA1 mutation	Ovarian Cancer	olaparib + AZD1775 Sensitive: C3 – Early Trials olaparib + AZD1775 Sensitive : C3	olaparib + AZD1775 Sensitive: C3 – Early Trials olaparib + AZD1775 Sensitive : C3
TP53 mutation	Colorectal Cancer	TP53 mutation	Colorectal Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
KRAS G13	Colorectal Cancer	KRAS G13	Colorectal Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
KRAS G12	Colorectal Cancer	KRAS G12	Colorectal Cancer	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
BRCA1 mutation	Ovarian Serous Adenocarcinoma	BRCA1 mutation	Ovarian Serous Adenocarcinoma	AZD1775 Sensitive: C4 – Case Studies AZD1775 Sensitive : C4	AZD1775 Sensitive: C4 – Case Studies AZD1775 Sensitive : C4
WEE1 mutation + PKMYT1 overexpression	Solid Tumor	WEE1 mutation + PKMYT1 overexpression	Solid Tumor	AZD1775 Resistant: C4 – Case Studies AZD1775 Resistant : C4	AZD1775 Resistant: C4 – Case Studies AZD1775 Resistant : C4
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D	AZD1775 Sensitive: D – Preclinical AZD1775 Sensitive : D
PDGFRA mutation	Gastrointestinal Stromal Tumor	PDGFRA mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D
KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D	AZD1775 + avapritinib Sensitive: D – Preclinical AZD1775 + avapritinib Sensitive : D
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
TP53 mutation	Small Cell Lung Cancer	TP53 mutation	Small Cell Lung Cancer	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D
TP53 mutation	Squamous Cell Carcinoma of Head and Neck	TP53 mutation	Squamous Cell Carcinoma of Head and Neck	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D	AZD1775 + VIC-1911 Sensitive: D – Preclinical AZD1775 + VIC-1911 Sensitive : D

adavosertib (AZD1775)

Associations
(55)

Associations
(55)

adavosertib (AZD1775)

Associations(55)

Associations(55)

Associations
(55)

Associations
(55)